FAX RECEIVED

OCI O 7 SUUS

GROUP 1600

FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY

October 7, 2002

TO:

Examiner Stephen Rawlings

Group 1642 703-305-3008

FROM

Justin D. Karjala

Celera Genomics Corp.

(240) 453-3812

FAX NO:

(703) 872-9306

OF PAGES (incl. cover):

8

OFF

Re:

U.S. Serial No. 09/820,003, filed March 29, 2001

Entitled "ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND

USES THEREOF"

Atty. Docket No.: CL001196

A Preliminary Amendment (Restriction Election), a Statement Regarding Duty of Disclosure, and a Petition for a One-Month Extension of Time in the above-identified application follows.

The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail. Thank you for your cooperation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: MERKULOV et al.

Art Unit: 1642

Serial No. 09/820,003

Examiner: S. Rawlings

Filed: March 29, 2001

Atty. Docket: CL001196

For: ISOLATED HUMAN RAS-LIKE PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE HUMAN RAS-LIKE PROTEINS, AND USES THEREOF

Statement Regarding Duty Of Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

By Facsimile

Sir:

This statement is to inform the United States of Patent and Trademark Office that Applicants and their representative have made a good faith effort in searching prior art relating to this invention.

No prior art material to patentability of the present invention has been found. The closest information associated with the invention is disclosed in Figures 1 and 2 in the top BLAST search results. However, this information, by itself or in combination with other information, does not constitute a prima facie case of unpatentability of any of the pending claims. Thus, it does not defeat the novelty of the present invention and the actual underlying references for the top BLAST hits are not being provided.

Respectfully submitted,

CELERA GENOMICS

Date: October 7, 2002

Celera Genomics Corporation 45 West Gude Drive, C2-4#20 Rockville, MD 20850

Tel: 240-453-3812 / Fax: 240-453-3084

Histin D. Karjala, Reg No. 43,704